Company intelligence / Profile preview

BioCardia Lifesciences

Sunnyvale, California, United States

Ownership: Private
Employees: ~22
Development stage: Other

Overview

BioCardia is in Phase 3 trials for its lead autologous cell therapy CardiAMP for ischemic heart failure and chronic myocardial ischemia. Early blinded data from the CardiAMP trial shows meaningful improvement over expected declines in patients, with no significant safety concerns noted by multiple DSMB reviews. The allogeneic pipeline is in earlier clinical stages. Topline data from the CardiAMP chronic myocardial ischemia trial show improved exercise tolerance and reduced angina at 6 months.

Therapeutic areas: CardiovascularPulmonology
Modalities: Cell therapyAutologous cell therapyAllogeneic cell therapyDevice
Industry: Biotech

Partnerships

CellProthera (academic/clinical trial collaboration)Selective device partnerships (Helix system outlicensed selectively)

Beyond the preview

Go deeper on BioCardia Lifesciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioCardia Lifesciences.

Explore the full profile